CN Patent

CN101203211A — 药物组合物

Assigned to Leo Oslo Peter & Richer Co ltd · Expires 2008-06-18 · 18y expired

What this patent protects

本发明提供含有4－喹唑啉胺二甲苯磺酸盐的口服药物制剂以及使用所述口服药物制剂来治疗以erbB家族PTK活性异常为特征的疾病的方法。

USPTO Abstract

本发明提供含有4－喹唑啉胺二甲苯磺酸盐的口服药物制剂以及使用所述口服药物制剂来治疗以erbB家族PTK活性异常为特征的疾病的方法。

Drugs covered by this patent

lapatinib-ditosylate (LAPATINIB DITOSYLATE)

Patent Metadata

Patent number: CN101203211A
Jurisdiction: CN
Classification: —
Expires: 2008-06-18
Drug substance claim: No
Drug product claim: No
Assignee: Leo Oslo Peter & Richer Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.